title: The preparation and evaluation of poly(epsilon-caprolactone) microparticles containing both a lipophilic and a hydrophilic drug.
abstract: An original dosage form for oral delivery based on the encapsulation of both, lipophilic and hydrophilic drugs, in poly(epsilon-caprolactone) (PCL) microparticles prepared either by the oil-in-water (o/w) or the water-in-oil-in-water (w/o/w) solvent evaporation method was developed. Microparticles were characterized in terms of morphology, size, encapsulation efficiency and drug release. The physical state of the drugs and the polymer was determined by scanning electron microscopy (SEM), X-ray powder diffractometry, and differential scanning calorimetry (DSC). Nifedipine (calcium antagonist) and propranolol HCl (beta-blocker), used for the treatment of hypertension, were chosen as lipophilic and hydrophilic drugs. The microparticles were spherical with diameters in the range of 191-351 microm by the o/w-method, and in the range of 302-477 microm by the w/o/w-method. The encapsulation efficiency (EE) was 91% for nifedipine and 37% for propranolol HCl with the o/w-method, and 83% for nifedipine and 57% for propranolol HCl with the w/o/w-method. DSC and X-ray diffraction studies showed that PCL maintained its semi-crystalline structure, while the drugs were either dispersed or dissolved in the polymer. In vitro release studies revealed a controlled release of nifedipine and propranolol HCl from microparticles prepared by the o/w-method; a burst release of propranolol HCl was observed from microparticles prepared by the w/o/w-method. In conclusion, microparticles containing both a hydrophilic and a lipophilic drug were successfully prepared.
authors.affiliation: Laboratoire de Pharmacie Galénique et Biopharmacie, Université de Nancy I, 5 rue A. Lebrun, BP 403 54001, Nancy, France.
authors.forename: M
authors.initials: M
authors.lastname: Hombreiro Pérez
authors.forename: C
authors.initials: C
authors.lastname: Zinutti
authors.forename: A
authors.initials: A
authors.lastname: Lamprecht
authors.forename: N
authors.initials: N
authors.lastname: Ubrich
authors.forename: A
authors.initials: A
authors.lastname: Astier
authors.forename: M
authors.initials: M
authors.lastname: Hoffman
authors.forename: R
authors.initials: R
authors.lastname: Bodmeier
authors.forename: P
authors.initials: P
authors.lastname: Maincent
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000032:analysis / Q000737:chemistry; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000032:analysis / Q000737:chemistry; D002152:Calorimetry, Differential Scanning; D004655:Emulsions; D008855:Microscopy, Electron, Scanning; D008863:Microspheres; D009543:Nifedipine / Q000008:administration & dosage / Q000032:analysis / Q000737:chemistry; D010316:Particle Size; D011091:Polyesters / Q000737:chemistry*; D011433:Propranolol / Q000008:administration & dosage / Q000032:analysis / Q000737:chemistry; D012995:Solubility; D014961:X-Ray Diffraction
chemical_list: D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers; D004655:Emulsions; D011091:Polyesters; C016240:polycaprolactone; D011433:Propranolol; D009543:Nifedipine